vs
德康医疗（DXCM）与STIFEL FINANCIAL CORP（SF）财务数据对比。点击上方公司名可切换其他公司
STIFEL FINANCIAL CORP的季度营收约是德康医疗的1.3倍（$1.7B vs $1.3B），德康医疗净利率更高（21.2% vs 15.1%，领先6.1%），德康医疗同比增速更快（21.6% vs 17.7%），过去两年STIFEL FINANCIAL CORP的营收复合增速更高（44.4% vs 12.0%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
司迪富金融是美国跨国独立投资银行及金融服务提供商，总部位于密苏里州圣路易斯市中心。其历史可追溯至1890年成立的Altheimer & Rawlings投资公司，1983年正式以Stifel为名成立，1986年11月24日在纽约证券交易所挂牌上市，为全球客户提供多元化金融服务。
DXCM vs SF — 直观对比
营收规模更大
SF
是对方的1.3倍
$1.3B
营收增速更快
DXCM
高出3.8%
17.7%
净利率更高
DXCM
高出6.1%
15.1%
两年增速更快
SF
近两年复合增速
12.0%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.7B |
| 净利润 | $267.3M | $251.4M |
| 毛利率 | 62.9% | — |
| 营业利润率 | 25.6% | 30.8% |
| 净利率 | 21.2% | 15.1% |
| 营收同比 | 21.6% | 17.7% |
| 净利润同比 | 153.6% | 374.4% |
| 每股收益（稀释后） | $0.67 | $1.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMSF
| Q1 26 | $1.3B | $1.7B | ||
| Q4 25 | $1.3B | $1.1B | ||
| Q3 25 | $1.2B | $962.6M | ||
| Q2 25 | $1.2B | $838.9M | ||
| Q1 25 | $1.0B | $842.5M | ||
| Q4 24 | $1.1B | $916.0M | ||
| Q3 24 | $994.2M | $810.9M | ||
| Q2 24 | $1.0B | $798.9M |
净利润DXCMSF
| Q1 26 | $267.3M | $251.4M | ||
| Q4 25 | $267.3M | $264.4M | ||
| Q3 25 | $283.8M | $211.4M | ||
| Q2 25 | $179.8M | $155.1M | ||
| Q1 25 | $105.4M | $53.0M | ||
| Q4 24 | $151.7M | $244.0M | ||
| Q3 24 | $134.6M | $158.5M | ||
| Q2 24 | $143.5M | $165.3M |
毛利率DXCMSF
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
营业利润率DXCMSF
| Q1 26 | 25.6% | 30.8% | ||
| Q4 25 | 25.6% | 27.3% | ||
| Q3 25 | 20.1% | 29.7% | ||
| Q2 25 | 18.4% | 25.5% | ||
| Q1 25 | 12.9% | 7.5% | ||
| Q4 24 | 17.0% | 29.1% | ||
| Q3 24 | 15.3% | 26.7% | ||
| Q2 24 | 15.7% | 28.4% |
净利率DXCMSF
| Q1 26 | 21.2% | 15.1% | ||
| Q4 25 | 21.2% | 23.5% | ||
| Q3 25 | 23.5% | 22.0% | ||
| Q2 25 | 15.5% | 18.5% | ||
| Q1 25 | 10.2% | 6.3% | ||
| Q4 24 | 13.6% | 26.6% | ||
| Q3 24 | 13.5% | 19.5% | ||
| Q2 24 | 14.3% | 20.7% |
每股收益（稀释后）DXCMSF
| Q1 26 | $0.67 | $1.48 | ||
| Q4 25 | $0.67 | $2.30 | ||
| Q3 25 | $0.70 | $1.84 | ||
| Q2 25 | $0.45 | $1.34 | ||
| Q1 25 | $0.27 | $0.39 | ||
| Q4 24 | $0.37 | $2.10 | ||
| Q3 24 | $0.34 | $1.34 | ||
| Q2 24 | $0.35 | $1.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.7B | $332.3M |
| 总资产 | $6.3B | $42.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DXCMSF
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $2.3B | ||
| Q3 25 | $1.8B | $3.2B | ||
| Q2 25 | $1.2B | $1.9B | ||
| Q1 25 | $904.9M | $2.7B | ||
| Q4 24 | $606.1M | $2.6B | ||
| Q3 24 | $621.2M | $1.9B | ||
| Q2 24 | $939.2M | $2.6B |
总债务DXCMSF
| Q1 26 | — | — | ||
| Q4 25 | — | $617.4M | ||
| Q3 25 | — | $617.2M | ||
| Q2 25 | — | $617.0M | ||
| Q1 25 | — | $616.8M | ||
| Q4 24 | — | $616.6M | ||
| Q3 24 | — | $616.4M | ||
| Q2 24 | — | $1.1B |
股东权益DXCMSF
| Q1 26 | $2.7B | $332.3M | ||
| Q4 25 | $2.7B | $6.0B | ||
| Q3 25 | $2.7B | $5.8B | ||
| Q2 25 | $2.6B | $5.6B | ||
| Q1 25 | $2.3B | $5.5B | ||
| Q4 24 | $2.1B | $5.7B | ||
| Q3 24 | $2.0B | $5.6B | ||
| Q2 24 | $2.4B | $5.4B |
总资产DXCMSF
| Q1 26 | $6.3B | $42.9B | ||
| Q4 25 | $6.3B | $41.3B | ||
| Q3 25 | $7.5B | $41.7B | ||
| Q2 25 | $7.3B | $39.9B | ||
| Q1 25 | $6.8B | $40.4B | ||
| Q4 24 | $6.5B | $39.9B | ||
| Q3 24 | $6.4B | $38.9B | ||
| Q2 24 | $6.8B | $37.8B |
负债/权益比DXCMSF
| Q1 26 | — | — | ||
| Q4 25 | — | 0.10× | ||
| Q3 25 | — | 0.11× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.21× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DXCM
暂无分部数据
SF
| Other | $506.7M | 30% |
| Asset management | $459.5M | 28% |
| Investment banking | $341.4M | 20% |
| Commissions | $207.8M | 12% |
| Principal transactions | $150.2M | 9% |
